Janux Therapeutics, Inc. (JANX) – What Are Researchers Saying About This Stock?

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received an average rating of “Moderate Buy” from the fifteen research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $36.46.

Several analysts have commented on JANX shares. Guggenheim lowered their price objective on shares of Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a report on Friday, August 7th. Stifel Nicolaus set a $35.00 target price on Janux Therapeutics in a report on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Monday, July 20th. Truist Financial restated a “buy” rating and set a $26.00 price target (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th. Finally, TD Cowen upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th.

Janux Therapeutics Trading Down 5.3%

Shares of NASDAQ JANX opened at $17.18 on Friday. Janux Therapeutics has a 12 month low of $12.12 and a 12 month high of $35.34. The firm has a market capitalization of $1.05 billion, a PE ratio of -10.48 and a beta of 2.40. The firm has a fifty day simple moving average of $17.50 and a two-hundred day simple moving average of $15.74.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The firm had revenue of $10.27 million for the quarter, compared to analysts’ expectations of $19.07 million. On average, sell-side analysts predict that Janux Therapeutics will post -1.70 earnings per share for the current year.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in JANX. GAMMA Investing LLC boosted its holdings in shares of Janux Therapeutics by 67.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,642 shares of the company’s stock valued at $28,000 after buying an additional 661 shares in the last quarter. Congress Asset Management Co. increased its stake in shares of Janux Therapeutics by 24.6% in the 3rd quarter. Congress Asset Management Co. now owns 84,211 shares of the company’s stock worth $1,455,000 after acquiring an additional 16,601 shares in the last quarter. Versant Capital Management Inc increased its stake in shares of Janux Therapeutics by 58.7% in the 3rd quarter. Versant Capital Management Inc now owns 4,150 shares of the company’s stock worth $72,000 after acquiring an additional 1,535 shares in the last quarter. State Street Corp lifted its position in Janux Therapeutics by 22.0% during the 2nd quarter. State Street Corp now owns 3,004,899 shares of the company’s stock valued at $46,155,000 after acquiring an additional 540,882 shares during the period. Finally, WINTON GROUP Ltd lifted its position in Janux Therapeutics by 31.8% during the 2nd quarter. WINTON GROUP Ltd now owns 90,300 shares of the company’s stock valued at $1,387,000 after acquiring an additional 21,800 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California, developing cancer immunotherapies designed to activate the immune system selectively within the tumor microenvironment. The company’s technology is intended to direct T cells toward cancer cells while limiting activation in healthy tissues.

Janux’s core technology platform, known as TRACTr, uses conditionally activated T-cell engager molecules designed to remain masked in circulation and become activated by proteases that are more prevalent in tumors.